• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMC
Click for more information
0.00% 7.5¢

IMMURON LIMITED - Announcements

Market Cap $21.88M  ! watchlist Created with Sketch. Add to my watchlist

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMC Company Update on CDI Clinical Trial and New Strategic FocusPRICE SENSITIVE19/03/19
IMC Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
IMC Travelan FY19 Update and Expansion into North AmericaPRICE SENSITIVE29/01/19
IMC Form F-3PRICE SENSITIVE15/01/19
IMC Immuron Receives $1.19M R&D Tax Concession RefundPRICE SENSITIVE03/01/19
IMC Change in substantial holding29/11/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)27/11/18
IMC Appendix 3Y - Change of Director's Interest Notice (PA)27/11/18
IMC Appendix 3Y - Change of Director's Interest Notice (RJB)27/11/18
IMC Appendix 3B27/11/18
IMC Results of Meeting19/11/18
IMC IMC Appoints Experienced US Based Biotech Executive as CEOPRICE SENSITIVE19/11/18
IMC NASH clinical trial presentation & continued revenue growthPRICE SENSITIVE09/11/18
IMC Annual Report 2018 on Form 20-F & XBRL data filed with SEC01/11/18
IMC IMC's CEO Interviewed in US on the RedChip Money Report16/10/18
IMC Notice of Annual General Meeting/Proxy Form11/10/18
IMC Notice of Annual General Meeting/Proxy Form10/10/18
IMC Corporate Governance Statement27/09/18
IMC Appendix 4G27/09/18
IMC Annual Report27/09/18
IMC US DoD Report Travelan Protects Against Shigella in PrimatesPRICE SENSITIVE05/09/18
IMC Preliminary Final ReportPRICE SENSITIVE30/08/18
IMC Initial Director's Interest Notice (RJB)31/07/18
IMC Change in substantial holding30/07/18
IMC Immuron Reports Record RevenuePRICE SENSITIVE25/07/18 download Created with Sketch. 872.69KB
IMC Appendix 3B ESOP17/07/18 download Created with Sketch. 1.14MB
IMC US Department of Defense Research Collaboration Moves AheadPRICE SENSITIVE16/07/18 download Created with Sketch. 881.93KB
IMC European Patent Gramted for Nash TreatmentPRICE SENSITIVE11/07/18 download Created with Sketch. 782.89KB
IMC Resignation of Joint Company Secretary29/06/18 download Created with Sketch. 695.6KB
IMC Immuron Announces Board AppointmentPRICE SENSITIVE26/06/18 download Created with Sketch. 815.87KB
IMC Trading halt request25/06/18 download Created with Sketch. 541.86KB
IMC Trading HaltPRICE SENSITIVE25/06/18 download Created with Sketch. 221.37KB
IMC IMC Preclinical Study Reports Reduction in Colitis SymptomsPRICE SENSITIVE08/05/18
IMC Immuron CEO to Present at RedChip Global Online Growth Conf24/04/18
IMC Travelan Sales Continue to Soar in Third Quarter of FY2018PRICE SENSITIVE23/04/18
IMC Becoming a substantial holder20/03/18
IMC ASX Documentation Request - Reduction of Capital (Nov 2017)19/03/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)19/03/18
IMC Appendix 3B & 708A Notice (Placement to US Fund Allotment)16/03/18
IMC Immuron Announces A$5.1M Private Placement to U.S. FundPRICE SENSITIVE14/03/18
IMC Immuron Progresses Discussions with Institutional FundsPRICE SENSITIVE13/03/18
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw13/03/18
IMC Trading Halt Request12/03/18
IMC Trading HaltPRICE SENSITIVE12/03/18
IMC Immuron Reports Positive Results in NASH Clinical TrialPRICE SENSITIVE08/03/18
IMC Correction to False and Misleading News ReleasePRICE SENSITIVE07/03/18
IMC Trading HaltPRICE SENSITIVE07/03/18
IMC Appendix 4D - Half Year Financial Report - 31 Dec 2017PRICE SENSITIVE28/02/18
IMC Travelan Revenue Grows Significantly in US and AustraliaPRICE SENSITIVE16/02/18
IMC IMC Enrols First Patients in IMM529 C. Difficile Study31/01/18
IMC US Defence Depart Report-Travelan Targets Priority PathogensPRICE SENSITIVE30/01/18
IMC Immuron to Receive $2.16M R&D Tax Concession Cash RefundPRICE SENSITIVE23/01/18
IMC Immuron Appoints Grant Thornton as Company Auditors18/01/18
IMC CEO to Present on US Investor TV Show and at Biotech Conf10/01/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)22/12/17
IMC Appendix 3Y - Change of Director's Interest Notice (SA)22/12/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)22/12/17
IMC Appendix 3B14/12/17
IMC Van Leeuwenhoeck Institute Updates Immuron Research Coverage22/11/17
IMC Immuron Granted US Patent for NASH TreatmentPRICE SENSITIVE14/11/17
IMC Results of 2017 Annual General Meeting13/11/17
IMC Immuron Successfully Completes NASH Phase II Clinical StudyPRICE SENSITIVE09/11/17
IMC Travelan Experiences Strong Q1 FY2018 Sales GrowthPRICE SENSITIVE08/11/17
IMC Immuron Lodges Form 20F USA Annual Report03/11/17
IMC Notice of Annual General Meeting & Proxy Form18/10/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)10/10/17
IMC Corporate Governance Statement28/09/17
IMC Appendix 4G28/09/17
IMC Annual Report28/09/17
IMC Appendix 3Y - Change of Director's Interest Notice (DP)11/09/17
IMC Form 605 - Ceasing to be Substantial Shareholder (Retzos)08/09/17
IMC Appendix 4E Preliminary Final Report (30 June 2017)PRICE SENSITIVE31/08/17
IMC Immuron Opens Clinical Site to Commence C.Diff CDI StudyPRICE SENSITIVE28/08/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)28/08/17
IMC Updated Immuron Securities Trading Policy17/08/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)15/08/17
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw15/08/17
IMC Immuron Approved to Commence Clinical Study in C.DifficilePRICE SENSITIVE09/08/17
IMC Immuron to Present C.difficile Data at ClostPath 2017 ConferPRICE SENSITIVE08/08/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)08/08/17
IMC Immuron Presents NASH Interim-Results at BioShares Conferenc07/08/17
IMC Immuron Announces Management ChangesPRICE SENSITIVE03/08/17
IMC Appendix 3B28/07/17
IMC Success of NASH Phase II Interim Analysis Explained FurtherPRICE SENSITIVE13/07/17
IMC NASH PhaseII Interim Analysis Reveals Improved Liver EnzymesPRICE SENSITIVE10/07/17
IMC Pre-Clinical C. difficile Infection Results Paper PublishedPRICE SENSITIVE03/07/17
IMC Appendix 3Y - Change of Director's Interest Notice (RS)03/07/17
IMC Change of address26/06/17
IMC Appendix 3B - Issuance of Options (ESOP)23/06/17
IMC Ceasing to be a substantial holder20/06/17
IMC Change in substantial holding20/06/17
IMC Change in substantial holding20/06/17
IMC Change of Director's Interest Notice20/06/17
IMC Change of Director's Interest Notice20/06/17
IMC Change of Director's Interest Notice20/06/17
IMC Appendix 3B - Allotment of NASDAQ Listing16/06/17
IMC IMC Prices US IPO and NASDAQ Listing Raising USD$6.1MPRICE SENSITIVE09/06/17
IMC Trading HaltPRICE SENSITIVE08/06/17
IMC Travelan Increases Industry Presence - Conf & Sales UpdatePRICE SENSITIVE02/06/17
IMC Immuron Secures $1.5M R&D Cash Advance Loan FundingPRICE SENSITIVE01/06/17
IMC Company Update on CDI Clinical Trial and New Strategic Focus
19/03/19PRICE SENSITIVE
IMC Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
IMC Travelan FY19 Update and Expansion into North America
29/01/19PRICE SENSITIVE
IMC Form F-3
15/01/19PRICE SENSITIVE
IMC Immuron Receives $1.19M R&D Tax Concession Refund
03/01/19PRICE SENSITIVE
IMC Change in substantial holding
29/11/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
27/11/18
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
27/11/18
IMC Appendix 3Y - Change of Director's Interest Notice (RJB)
27/11/18
IMC Appendix 3B
27/11/18
IMC Results of Meeting
19/11/18
IMC IMC Appoints Experienced US Based Biotech Executive as CEO
19/11/18PRICE SENSITIVE
IMC NASH clinical trial presentation & continued revenue growth
09/11/18PRICE SENSITIVE
IMC Annual Report 2018 on Form 20-F & XBRL data filed with SEC
01/11/18
IMC IMC's CEO Interviewed in US on the RedChip Money Report
16/10/18
IMC Notice of Annual General Meeting/Proxy Form
11/10/18
IMC Notice of Annual General Meeting/Proxy Form
10/10/18
IMC Corporate Governance Statement
27/09/18
IMC Appendix 4G
27/09/18
IMC Annual Report
27/09/18
IMC US DoD Report Travelan Protects Against Shigella in Primates
05/09/18PRICE SENSITIVE
IMC Preliminary Final Report
30/08/18PRICE SENSITIVE
IMC Initial Director's Interest Notice (RJB)
31/07/18
IMC Change in substantial holding
30/07/18
IMC Immuron Reports Record Revenue
25/07/18PRICE SENSITIVE download Created with Sketch. 872.69KB
IMC Appendix 3B ESOP
17/07/18 download Created with Sketch. 1.14MB
IMC US Department of Defense Research Collaboration Moves Ahead
16/07/18PRICE SENSITIVE download Created with Sketch. 881.93KB
IMC European Patent Gramted for Nash Treatment
11/07/18PRICE SENSITIVE download Created with Sketch. 782.89KB
IMC Resignation of Joint Company Secretary
29/06/18 download Created with Sketch. 695.6KB
IMC Immuron Announces Board Appointment
26/06/18PRICE SENSITIVE download Created with Sketch. 815.87KB
IMC Trading halt request
25/06/18 download Created with Sketch. 541.86KB
IMC Trading Halt
25/06/18PRICE SENSITIVE download Created with Sketch. 221.37KB
IMC IMC Preclinical Study Reports Reduction in Colitis Symptoms
08/05/18PRICE SENSITIVE
IMC Immuron CEO to Present at RedChip Global Online Growth Conf
24/04/18
IMC Travelan Sales Continue to Soar in Third Quarter of FY2018
23/04/18PRICE SENSITIVE
IMC Becoming a substantial holder
20/03/18
IMC ASX Documentation Request - Reduction of Capital (Nov 2017)
19/03/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
19/03/18
IMC Appendix 3B & 708A Notice (Placement to US Fund Allotment)
16/03/18
IMC Immuron Announces A$5.1M Private Placement to U.S. Fund
14/03/18PRICE SENSITIVE
IMC Immuron Progresses Discussions with Institutional Funds
13/03/18PRICE SENSITIVE
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw
13/03/18
IMC Trading Halt Request
12/03/18
IMC Trading Halt
12/03/18PRICE SENSITIVE
IMC Immuron Reports Positive Results in NASH Clinical Trial
08/03/18PRICE SENSITIVE
IMC Correction to False and Misleading News Release
07/03/18PRICE SENSITIVE
IMC Trading Halt
07/03/18PRICE SENSITIVE
IMC Appendix 4D - Half Year Financial Report - 31 Dec 2017
28/02/18PRICE SENSITIVE
IMC Travelan Revenue Grows Significantly in US and Australia
16/02/18PRICE SENSITIVE
IMC IMC Enrols First Patients in IMM529 C. Difficile Study
31/01/18
IMC US Defence Depart Report-Travelan Targets Priority Pathogens
30/01/18PRICE SENSITIVE
IMC Immuron to Receive $2.16M R&D Tax Concession Cash Refund
23/01/18PRICE SENSITIVE
IMC Immuron Appoints Grant Thornton as Company Auditors
18/01/18
IMC CEO to Present on US Investor TV Show and at Biotech Conf
10/01/18
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
22/12/17
IMC Appendix 3Y - Change of Director's Interest Notice (SA)
22/12/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
22/12/17
IMC Appendix 3B
14/12/17
IMC Van Leeuwenhoeck Institute Updates Immuron Research Coverage
22/11/17
IMC Immuron Granted US Patent for NASH Treatment
14/11/17PRICE SENSITIVE
IMC Results of 2017 Annual General Meeting
13/11/17
IMC Immuron Successfully Completes NASH Phase II Clinical Study
09/11/17PRICE SENSITIVE
IMC Travelan Experiences Strong Q1 FY2018 Sales Growth
08/11/17PRICE SENSITIVE
IMC Immuron Lodges Form 20F USA Annual Report
03/11/17
IMC Notice of Annual General Meeting & Proxy Form
18/10/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
10/10/17
IMC Corporate Governance Statement
28/09/17
IMC Appendix 4G
28/09/17
IMC Annual Report
28/09/17
IMC Appendix 3Y - Change of Director's Interest Notice (DP)
11/09/17
IMC Form 605 - Ceasing to be Substantial Shareholder (Retzos)
08/09/17
IMC Appendix 4E Preliminary Final Report (30 June 2017)
31/08/17PRICE SENSITIVE
IMC Immuron Opens Clinical Site to Commence C.Diff CDI Study
28/08/17PRICE SENSITIVE
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
28/08/17
IMC Updated Immuron Securities Trading Policy
17/08/17
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
15/08/17
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw
15/08/17
IMC Immuron Approved to Commence Clinical Study in C.Difficile
09/08/17PRICE SENSITIVE
IMC Immuron to Present C.difficile Data at ClostPath 2017 Confer
08/08/17PRICE SENSITIVE
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
08/08/17
IMC Immuron Presents NASH Interim-Results at BioShares Conferenc
07/08/17
IMC Immuron Announces Management Changes
03/08/17PRICE SENSITIVE
IMC Appendix 3B
28/07/17
IMC Success of NASH Phase II Interim Analysis Explained Further
13/07/17PRICE SENSITIVE
IMC NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes
10/07/17PRICE SENSITIVE
IMC Pre-Clinical C. difficile Infection Results Paper Published
03/07/17PRICE SENSITIVE
IMC Appendix 3Y - Change of Director's Interest Notice (RS)
03/07/17
IMC Change of address
26/06/17
IMC Appendix 3B - Issuance of Options (ESOP)
23/06/17
IMC Ceasing to be a substantial holder
20/06/17
IMC Change in substantial holding
20/06/17
IMC Change in substantial holding
20/06/17
IMC Change of Director's Interest Notice
20/06/17
IMC Change of Director's Interest Notice
20/06/17
IMC Change of Director's Interest Notice
20/06/17
IMC Appendix 3B - Allotment of NASDAQ Listing
16/06/17
IMC IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M
09/06/17PRICE SENSITIVE
IMC Trading Halt
08/06/17PRICE SENSITIVE
IMC Travelan Increases Industry Presence - Conf & Sales Update
02/06/17PRICE SENSITIVE
IMC Immuron Secures $1.5M R&D Cash Advance Loan Funding
01/06/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
7.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $21.88M
Open High Low Value Volume
7.6¢ 7.6¢ 7.5¢ $9.071K 120.6K

Buyers (Bids)

No. Vol. Price($)
1 57518 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 10000 1
View Market Depth
Last trade - 15.45pm 22/11/2024 (20 minute delay) ?
IMC (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.